Clinical trial · Observational
Analysis of Percutaneous Ablations for Cancer Treatment
Prospective Analysis of Percutaneous Ablations for Cancer Treatment
NCT01563679CI-TRIAL-00014712completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a study involving patients with cancer who are referred by their treating physician for percutaneous locoregional therapies. Patient's clinical and radiology findings, pathology findings, survival, treatment responses, and complications after their locoregional therapy will be studied.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Effect of percutaneous and transarterial treatments for cancer in quality of life
- timeFrame
- 1 year
- description
- Patients will complete the QOL questionnare during their follow up visits after procedure. 1 month, 3 months, 6 months and 1 year.
Secondary outcomes (1)
- measure
- response rate to percutaneous and transarterial treatment for cancer
- timeFrame
- 1 month, 3 months, 6 months, 1 year.
- description
- Patients will be followed up 1, 3, 6 and 1year intervals after procedure.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18yrs of age * Cancer diagnosis * Candidate for Locoregional therapy * Willingness to sign informed consent Exclusion Criteria: * Unable to sign informed consent * Patients not eligible for locoregional therapies
References
Publications (0)
Data not yet available
No reference posted for this study.